New combo therapy aims to boost survival in adult leukemia
NCT ID NCT07495631
First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve higher rates of remission and longer survival. Participants will go through several phases of treatment over many months, with the option to add immunotherapy based on their preference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of chemotherapy drugs (vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, methotrexate), venetoclax, and immunotherapy (inotuzumab ozogamicin, blinatumomab)
- What this could lead to
- If successful, this approach could improve remission rates and long-term survival for adults with a hard-to-treat leukemia, potentially offering a more effective treatment option.
- What could go wrong
- This is a small, early-phase study with only 43 participants, so results may not apply to everyone. The intense chemotherapy and immunotherapy can cause serious side effects like infections and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- Leukemia Patients' hidden threat: fungal infections under microscope
- New combo therapy aims to cut chemo and boost survival in leukemia
- Triple threat: targeted drugs + CAR-T cells aim to beat a tough leukemia
- Adult leukemia patients get Kid-Style chemo combo in new trial
- New study opens door for CAR t therapy in patients with kidney disease